Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cancer Research

• Publication date

  2010-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-10-2286PMID 21098704PMCID PMC3057927
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nonsynonymous single nucleotide polymorphisms in DNA damage repair pathways and lung cancer risk

  2010cited by this paper
• A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

  2010cited by this paper
• The unstructured C-terminal tail of the 9-1-1 clamp subunit Ddc1 activates Mec1/ATR via two distinct mechanisms.

  2009cited by this paper
• Cell cycle kinases as therapeutic targets for cancer

  2009cited by this paper
• Mitochondrial Dysfunction Contributes to Oncogene-Induced Senescence

  2009cited by this paper
• ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.

  2009cited by this paper
• ATR and H2AX Cooperate in Maintaining Genome Stability under Replication Stress*

  2009cited by this paper
• Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model.

  2009cited by this paper
• Tim–Tipin dysfunction creates an indispensible reliance on the ATR–Chk1 pathway for continued DNA synthesis

  2009cited by this paper
• An Oncogene-Induced DNA Damage Model for Cancer Development

  2008cited by this paper
• Somatic mutations affect key pathways in lung adenocarcinoma

  2008cited by this paper
• ATR: an essential regulator of genome integrity

  2008cited by this paper
• Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss.

  2007cited by this paper
• The ATR pathway: fine-tuning the fork.

  2007cited by this paper
• Patterns of somatic mutation in human cancer genomes

  2007cited by this paper
• Non-transcriptional control of DNA replication by c-Myc

  2007cited by this paper
• Mutations in the ataxia telangiectasia and rad3‐related–checkpoint kinase 1 DNA damage response axis in colon cancers

  2007cited by this paper
• Deregulated Replication Licensing Causes DNA Fragmentation Consistent with Head-to-Tail Fork Collision

  2006cited by this paper
• Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints

  2006cited by this paper
• Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication

  2006cited by this paper
• Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites

  2006cited by this paper
• Ras Triggers Ataxia-telangiectasia-mutated and Rad-3-related Activation and Apoptosis through Sustained Mitogenic Signaling*

  2006cited by this paper
• Somatic mutations of the protein kinase gene family in human lung cancer.

  2005cited by this paper
• DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

  2005cited by this paper
• Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

  2005cited by this paper
• Inhibition of Human Chk1 Causes Increased Initiation of DNA Replication, Phosphorylation of ATR Targets, and DNA Breakage

  2005cited by this paper
• Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance.

  2005cited by this paper
• Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint.

  2005cited by this paper
• Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

  2004cited by this paper
• Targeting the checkpoint kinases: chemosensitization versus chemoprotection

  2004cited by this paper
• Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

  2004cited by this paper
• Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

  2004cited by this paper
• Classification of Proliferative Pulmonary Lesions of the Mouse

  2004cited by this paper
• ATR functions as a gene dosage‐dependent tumor suppressor on a mismatch repair‐deficient background

  2004cited by this paper
• Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation.

  2004cited by this paper
• Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance.

  2003cited by this paper
• ATR Homolog Mec1 Promotes Fork Progression, Thus Averting Breaks in Replication Slow Zones

  2002cited by this paper
• Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability.

  2002cited by this paper
• Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability.

  2001cited by this paper
• Somatic activation of the K-ras oncogene causes early onset lung cancer in mice

  2001cited by this paper
• Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.

  2001cited by this paper
• Suppression of spontaneous chromosomal rearrangements by S phase checkpoint functions in Saccharomyces cerevisiae.

  2001cited by this paper
• Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

  2001cited by this paper
• The DNA replication checkpoint response stabilizes stalled replication forks

  2001cited by this paper
• Regulation of DNA replication fork progression through damaged DNA by the Mec1/Rad53 checkpoint

  2001cited by this paper
• ATR disruption leads to chromosomal fragmentation and early embryonic lethality.

  2000cited by this paper
• Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.

  2000cited by this paper
• The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle.

  1994cited by this paper
• Extended culture of mouse embryo cells without senescence: inhibition by serum.

  1987cited by this paper

• Targeting ATR in Cancer therapy: A drug discovery perspective.

  2026cites this paper
• Defective DNA Damage Response is a Targetable Therapeutic Vulnerability in ESR1 Mutant Breast Cancer.

  2026cites this paper
• The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition

  2026cites this paper
• Resistance to BRAF inhibitors drives melanoma sensitivity to Chk1 inhibition

  2025cites this paper
• Radiotherapy resistance driven by Asparagine endopeptidase through ATR pathway modulation in breast cancer

  2025cites this paper
• Medicinal chemistry breakthroughs on ATM, ATR, and DNA-PK inhibitors as prospective cancer therapeutics

  2025cites this paper
• Cytogenetic signatures favoring metastatic organotropism in colorectal cancer

  2025cites this paper
• Claspin and Cancer: Where Are We Now?

  2025cites this paper
• Targeting ATR offers multifaceted treatment strategies involving RAD51-mediated compensatory DNA repair in bladder cancer

  2025cites this paper
• Targeting DNA Damage Repair Pathways Beyond PARP Inhibition

  2025cites this paper
• Oncogenic RAS in Cancers from the DNA Replication Stress and Senescence Perspective

  2024cites this paper
• Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations

  2024cites this paper
• Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets

  2024cites this paper
• Tolerance of Oncogene-Induced Replication Stress: A Fuel for Genomic Instability

  2024cites this paper
• Low PPP2R2A expression promotes sensitivity to CHK1 inhibition in high-grade serous ovarian cancer

  2024cites this paper
• Unveiling Tumorigenesis Mechanisms and Drug Therapy in Neuroblastoma by Mass Spectrometry Based Proteomics

  2024cites this paper
• Unravelling the molecular basis of PARP inhibitor resistance in prostate cancer with homologous recombination repair deficiency.

  2024cites this paper
• Comparative proteomic landscape, gene expression profiling, and hotspot HER2 and PIK3CA alterations in trastuzumab-sensitive and resistant HER2-positive breast cancer cell line

  2024cites this paper
• The KRAS, ATR and CHEK1 expression levels in endometrial cancer are the risk factors predicting recurrence

  2024cites this paper
• Stochastic variation in the FOXM1 transcription program mediates replication stress tolerance

  2024cites this paper
• WEE1 Inhibition by AZD1775 Augments Colorectal Cancer Cells Susceptibility to VE-822-induced DNA Damage and Apoptosis

  2024cites this paper
• RNF4 sustains Myc-driven tumorigenesis by facilitating DNA replication

  2024cites this paper
• p53-dependent crosstalk between DNA replication integrity and redox metabolism mediated through a NRF2-PARP1 axis

  2024cites this paper
• Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes

  2024cites this paper
• Cell cycle dysregulation in cancer.

  2024cites this paper
• Synergistic lethality between auranofin-induced oxidative DNA damage and ATR inhibition in cancer cells.

  2023cites this paper
• Recent progress of targeted nanocarriers in diagnostic, therapeutic, and theranostic applications in colorectal cancer.

  2023cites this paper
• Inhibition of Replication Origins and ATR Synergistically Activates the Innate Immune System in Cancer Cells

  2023cites this paper
• Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

  2023cites this paper
• Chemo-Phosphoproteomic Profiling with ATR Inhibitors Berzosertib and Gartisertib Uncovers New Biomarkers and DNA Damage Response Regulators

  2023cites this paper
• The “extreme phenotype approach” applied to male breast cancer allows the identification of rare variants of ATR as potential breast cancer susceptibility alleles

  2023cites this paper
• Novel Cellular Functions of ATR for Therapeutic Targeting: Embryogenesis to Tumorigenesis

  2023cites this paper
• An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress

  2023cites this paper
• Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

  2023cites this paper
• Emerging strategies for cancer therapy by ATR inhibitors

  2023cites this paper
• The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Pathways

  2022cites this paper
• Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies

  2022cites this paper
• Elimusertib outperforms standard of care chemotherapy in preclinical patient-derived pediatric solid tumor models

  2022cites this paper
• ATR Inhibitors in Platinum-Resistant Ovarian Cancer

  2022cites this paper
• Resistance to DNA repair inhibitors in cancer

  2022cites this paper
• Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma

  2022cites this paper
• RAS-mediated tumor stress adaptation and the targeting opportunities it presents

  2022cites this paper
• LAP2α preserves genome integrity through assisting RPA deposition on damaged chromatin

  2022cites this paper
• Mechanisms used by cancer cells to tolerate drug-induced replication stress.

  2022cites this paper
• CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models

  2021cites this paper
• A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade.

  2021cites this paper
• Targeting the DNA replication stress phenotype of KRAS mutant cancer cells

  2021cites this paper
• Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers

  2021cites this paper
• Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer

  2021cites this paper
• Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability

  2021cites this paper
• Critical DNA damaging pathways in tumorigenesis.

  2021cites this paper
• Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives

  2021cites this paper
• ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomide

  2021cites this paper
• Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer

  2021cites this paper
• ATR inhibition enables complete tumour regression in ALK-driven NB mouse models

  2021cites this paper
• High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells

  2021cites this paper
• Inhibition of the DSB repair protein RAD51 potentiates the cytotoxic efficacy of doxorubicin via promoting apoptosis-related death pathways.

  2021cites this paper
• Genetic drivers and cells of origin in sarcomagenesis

  2021cites this paper
• MYC-Induced Replicative Stress: A Double-Edged Sword for Cancer Development and Treatment

  2021cites this paper
• Genome instability and lymphoma.

  2021cites this paper
• Targeting the replication stress response through synthetic lethal strategies in cancer medicine.

  2021cites this paper
• Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment

  2021cites this paper
• Progress towards a clinically-successful ATR inhibitor for cancer therapy

  2021cites this paper
• Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress

  2021cites this paper
• DNA damage responses that enhance resilience to replication stress

  2021cites this paper
• Roles of Claspin in regulation of DNA replication, replication stress responses and oncogenesis in human cells

  2021cites this paper
• Oncogenic RAS sensitizes cells to drug-induced replication stress via transcriptional silencing of P53

  2021cites this paper
• ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer

  2020cites this paper
• Discovery and in silico evaluation of aminoarylbenzosuberene molecules as novel checkpoint kinase 1 inhibitor determinants.

  2020cites this paper
• Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences.

  2020cites this paper
• A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors

  2020cites this paper
• Exploiting replicative stress in gynecological cancers as a therapeutic strategy

  2020cites this paper
• SMARCA4 deficiency-associated heterochromatin induces intrinsic DNA replication stress and susceptibility to ATR inhibition in lung adenocarcinoma

  2020cites this paper
• Germline PALB2 Mutations in Cancers and Its Distinction From Somatic PALB2 Mutations in Breast Cancers

  2020cites this paper
• Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.

  2020cites this paper
• Therapeutic Targets and Opportunities in Endometrial Cancer: Update on Endocrine Therapy and Nonimmunotherapy Targeted Options.

  2020cites this paper
• Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility

  2020cites this paper
• Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

  2020cites this paper
• Harnessing DNA Replication Stress for Novel Cancer Therapy

  2020cites this paper
• Targeting the Ataxia Telangiectasia and Rad3 Signaling Pathway to Overcome Chemoresistance in Cancer

  2019cites this paper
• Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment.

  2019cites this paper
• Comparison of the different mechanisms of cytotoxicity induced by Checkpoint Kinase I inhibitors when used as single agents or in combination with DNA damage

  2019cites this paper
• Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner

  2019cites this paper
• From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers

  2019cites this paper
• Drug Combinatorial Therapies for Treatment of KRAS Mutated Lung Cancers.

  2019cites this paper
• The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

  2019cites this paper
• Exploiting DNA Replication Stress for Cancer Treatment.

  2019cites this paper
• Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?

  2019cites this paper
• DNA replication stress: oncogenes in the spotlight

  2019cites this paper
• Integration of pathway, cellular and genetic context reveals principles of synthetic lethality that affect reproducibility

  2019cites this paper
• Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities.

  2019cites this paper
• Targeting tumor microenvironment crosstalk throughgpcr receptors and pl3k pathway

  2019cites this paper
• Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras.

  2018cites this paper
• Diverse roles of RAD18 and Y-family DNA polymerases in tumorigenesis

  2018cites this paper
• The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response

  2018cites this paper
• Synthetically Lethal Interactions of ATM, ATR, and DNA-PKcs.

  2018cites this paper
• ATR-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells

  2018cites this paper
• Determining individual chromosome missegregation rates and the responses to aneuploidy in human cells

  2018cites this paper
• The DNA Damage Response: Roles in Cancer Etiology and Treatment

  2018cites this paper
• Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place.

  2018cites this paper